LUBRANO DI SCORPANIELLO, Ennio
 Distribuzione geografica
Continente #
NA - Nord America 5.712
EU - Europa 5.292
AS - Asia 429
SA - Sud America 30
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 14
AF - Africa 10
Totale 11.504
Nazione #
US - Stati Uniti d'America 5.691
IE - Irlanda 2.290
UA - Ucraina 532
IT - Italia 453
FI - Finlandia 440
AT - Austria 363
DE - Germania 323
SE - Svezia 319
CN - Cina 262
FR - Francia 253
GB - Regno Unito 191
IN - India 51
BE - Belgio 48
SG - Singapore 26
RU - Federazione Russa 25
CA - Canada 18
TR - Turchia 17
BR - Brasile 16
AU - Australia 15
IR - Iran 15
EU - Europa 14
VN - Vietnam 14
NL - Olanda 12
IL - Israele 9
ES - Italia 8
CH - Svizzera 6
CL - Cile 6
HR - Croazia 6
JP - Giappone 6
RO - Romania 6
CO - Colombia 4
EG - Egitto 4
GR - Grecia 4
IQ - Iraq 4
KZ - Kazakistan 4
MY - Malesia 4
PL - Polonia 4
CZ - Repubblica Ceca 3
TH - Thailandia 3
BD - Bangladesh 2
DK - Danimarca 2
ID - Indonesia 2
KR - Corea 2
LK - Sri Lanka 2
MA - Marocco 2
MX - Messico 2
NZ - Nuova Zelanda 2
PE - Perù 2
TW - Taiwan 2
ZA - Sudafrica 2
AR - Argentina 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
HK - Hong Kong 1
MK - Macedonia 1
NG - Nigeria 1
NO - Norvegia 1
PH - Filippine 1
PK - Pakistan 1
PT - Portogallo 1
SA - Arabia Saudita 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 11.504
Città #
Dublin 2.290
Jacksonville 1.319
Chandler 1.133
Wilmington 409
Vienna 361
Helsinki 303
Rome 263
Houston 248
San Mateo 247
Ann Arbor 185
Princeton 179
Woodbridge 146
Boardman 111
Dearborn 94
Beijing 62
Ashburn 55
Brussels 45
New York 43
Redwood City 41
Mountain View 36
Molise 34
Jinan 26
Nanjing 18
Falls Church 17
Shenyang 16
Ningbo 14
Auburn Hills 13
Leawood 13
Augusta 12
Haikou 12
Singapore 11
Ardabil 10
Dong Ket 10
Seattle 10
Borås 9
Chicago 9
Guangzhou 9
Los Angeles 9
Norwalk 9
Rockville 9
Esslingen am Neckar 8
London 8
Seelze 8
Taizhou 8
Zhengzhou 8
Changsha 7
Hefei 7
Milan 7
Monmouth Junction 7
Shanghai 7
Tianjin 7
Detroit 6
Fairfield 6
Nanchang 6
Simi Valley 6
São Paulo 6
Taiyuan 6
Chennai 5
Falkenstein 5
Kunming 5
San Francisco 5
St Louis 5
Tappahannock 5
Almaty 4
Fleet 4
Fuzhou 4
Greenford 4
Hebei 4
Jiaxing 4
Quzhou 4
Renton 4
Ariccia 3
Bangkok 3
Berlin 3
Cagliari 3
Castelfidardo 3
Costa 3
Fermignano 3
Florence 3
Frankfurt am Main 3
Hangzhou 3
Hanoi 3
Lanzhou 3
Mumbai 3
Novokuznetsk 3
Ottawa 3
Oxford 3
Rochester 3
San Genesio Ed Uniti 3
Sommatino 3
Torino 3
Warsaw 3
Amsterdam 2
Antwerpen 2
Athens 2
Avignon 2
Bangalore 2
Baotou 2
Borgo Val di Taro 2
Brescia 2
Totale 8.099
Nome #
An ultrasonographic study of enthesis in early psoriatic arthritis patients naive to traditional and biologic DMARDs treatment 121
Analysis of potential determinants for a treat-to-target strategy in psoriatic arthritis patients from a real-world setting 104
Venous thrombophilia in a patient with protein S deficiency, factor V Leiden and homozygous MTHFR C -> T677 mutation 101
Iperuricemia e rischio cardio-renale 99
Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study 98
La spondilodiscite delle spondiloartriti sieronegative 93
Validity, responsiveness and feasibility of an Italian version of the Canadian Occupational Performance Measure for patients with ankylosing spondylitis 92
Validity and reliability of an Italian version of the revised Leeds disability questionnaire for patients with ankylosing spondylitis 91
Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study. 90
The arthritis of coeliac disease: prevalence and pattern in 200 adult patients 88
Simple clinical indicators for early psoriatic arthritis detection. 87
Assessment of response to treatment, remission, and minimal disease activity in axial psoriatic arthritis treated with tumor necrosis factor inhibitors 87
Incidence of rheumatoid arthritis, psoriatic arthritis and polymyalgia rheumatica in an inland area of central Italy: results of the CAMPO-RHE study 87
Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs -- comparison of drugs and adverse reactions 86
Validity of the modified stoke ankylosing spondylitis spine score (M-SASSS) and of the bath ankylosing spondylitis radiology index (BASRI) for the radiological assessment of axial involvement in psoriatic arthritis. multicentre validation study. Part one. 85
Consensus on the management of patients with psoriatic arthritis in a dermatology setting 85
Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study 84
Etanercept in psoriatic arthritis 84
The performance of CASPAR criteria in early psoriatic arthritis - preliminary results from an Italian prospective multicentric study 83
Assessment of semaphorin 3A and its role in bone remodelling in a group of ankylosing spondylitis patients 83
Venous thrombophilia with severe mesenteric involvement associated to homozygosity for factor V Leiden and heterozygosity for G20210A mutation of prothrombin 82
Comparison of composite indices tailored for psoriatic arthritis treated with csDMARD and bDMARD: A cross-sectional analysis of a longitudinal cohort 82
Trauma and seronegative spondylarthropathy 81
Supervised training and home-based rehabilitation in patients with stabilized ankylosing spondylitis on TNF inhibitor treatment: a controlled clinical trial with a 12-month follow-up 81
Treatment options: NSAIDs and DMARDs 81
Subcorneal pustular dermatosis (Sneddon-Wilkinson syndrome): another cutaneous manifestation of SAPHO syndrome? 81
Tumour necrosis factor alpha inhibitor therapy and rehabilitation for the treatment of ankylosing spondylitis: A systematic review. 81
Unmet Needs in Axial Spondyloarthritis 81
Residual disease activity in rheumatoid arthritis patients treated with subcutaneous biologic drugs that achieved remission or low disease activity: a longitudinal observational study 81
Chronic periaortitis with retroperitoneal fibrosis successfully treated with first line tocilizumab monotherapy: a case report 81
Unmet needs in outcome measures of Psoriatic Arthritis: focus on axial radiographic and nail involvement 80
Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients 80
The adherence to ASAS classification criteria and to ASAS recommendations for the use of anti-TNH-alpha agents in axial spondyloarthritis. 79
Beyond TNF Inhibitors: New Pathways and Emerging Treatments for Psoriatic Arthritis 79
Elderly psoriatic arthritis patients on TNF-α blockers: results of an Italian multicenter study on minimal disease activity and drug discontinuation rate 79
Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey. 77
Secukinumab for ankylosing spondylitis and psoriatic arthritis 77
Updated guidelines for the management of axial disease in psoriatic arthritis 77
The arthritis of ulcerative colitis: clinical and genetic aspects 76
Defining low disease activity states in psoriatic arthritis using novel composite disease instruments 76
Assessment of subclinical atherosclerosis in ankylosing spondylitis: Correlations with disease activity indices 76
Mesenchimal stem cells: A possible role in the pathogenesis and treatment of spondyloarthritis 76
Patient education in psoriatic arthritis: a cross sectional study on knowledge by a validated self-administered questionnaire 75
Axonal degeneration in systemic sclerosis can be reverted by factors improving tissue oxygenation 75
Psoriatic disease: Clinical staging 75
The role of IL-17 in the treatment of psoriatic arthritis 75
The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept 75
Somatic perception in irritable bowel syndrome (IBS) patients with and without fibromyalgia (FMS). Does the severity of IBS influence the perception of somatic stimuli? 74
Validation of the Italian version of proposed GRAPPA flare questionnaire for patients with psoriatic arthritis 74
From clinical remission to residual disease activity in spondyloarthritis and its potential treatment implications 74
Measuring psoriatic disease in clinical practice. An expert opinion position paper. 73
Qualifying Unmet Needs and Improving Standards of Care in Psoriatic Arthritis. 73
Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis 73
Beyond early diagnosis: occult psoriatic arthritis 73
The assessment of knowledge in ankylosing spondylitis patients by a self-administered questionnaire 73
Predictors of loss of remission and disease flares in patients with axial spondyloarthritis receiving antitumor necrosis factor treatment: A retrospective study 73
An audit of anthropometric measurements by medical and physiotherapy staff in patients with ankylosing spondylitis 71
An overview of low disease activity and remission in psoriatic arthritis. 70
Is the Nail Psoriasis Severity Index reliable in the assessment of nail psoriasis by rheumatologists? 70
Aortic involvement in ankylosing spondylitis 70
ANTHROPOMETRIC MEASUREMENTS AND DISABILITY IN A OPEN FOLLOW UP STUDY ON ANKYLOSING SPONDYLITIS WITH COMBINED MEDICAL AND REHABILITATIVE TREATMENT 70
L’educazione del paziente affetto da artrite reumatoide. 70
Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-α drugs: an Italian multicenter study. 70
Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs 70
The effectiveness of rehabilitation in active ankylosing spondylitis assessed by the ASAS response criteria 70
An Assessment of Hand Erosive Osteoarthritis: Correlation of Radiographic Severity with Clinical, Functional and Laboratory Findings 70
The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy 70
Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection. 68
Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs 68
Subcutaneous anti-TNF alfa induced sustained minimal disease activity and remission in psoriatic arthritis patients: a retrospective study 68
Patient's global assessment as an outcome measure for psoriatic arthritis in clinical practice: A surrogate for measuring low disease activity? 68
Beyond the joint: Subclinical atherosclerosis in rheumatoid arthritis 67
Not simply a matter of psoriatic arthritis: epidemiology of rheumatic diseases in psoriatic patients. 67
Physical trauma triggers psoriasis in a patient with undifferentiated seronegative spondyloarthropathy 67
Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs 67
Pharmacoeconomic issues in psoriatic arthritis 66
Clues to the pathogenesis of psoriasis and psoriatic arthritis from imaging: a literature review 66
Joint symmetry in early and late rheumatoid and psoriatic arthritis: comparison with a mathematical model 66
Antiphospholipid syndrome, activated protein C resistance and mutation C -> T 677 in the MTHFR gene with juvenile pulmonary embolism. A case report 66
Lupus anticoagulant, ankylosing spondylitis, and thrombosis 66
New insights in occult psoriatic arthritis 66
Psoriatic arthritis spondylitis radiology index: a modified index for radiologic assessment of axial involvement in psoriatic arthritis 65
Outcome measures in psoriatic arthritis 65
Juvenile rheumatoid arthritis, Crohn's disease and Turner's syndrome: a novel association 64
Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis. 64
The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). 64
Emerging drugs for psoriatic arthritis 64
Reverse correlation between extent of colon involvement and number of affected joints in patients with ulcerative colitis and arthritis 64
Psoriatic arthritis (PA): a harmless disease? 64
Axial psoriatic arthritis: an intriguing clinical entity or a subset of an intriguing disease? 63
Assessment of psoriatic nail disease activity by rheumatologists 63
Psoriatic Arthritis and Psoriasis Projects in Italy: A Report from the GRAPPA 2011 Meeting 63
Bilateral renal artery occlusion in a patient with primary antiphospholipid antibody syndrome: thrombosis, vasculitis or both? 63
The definition and measurement of axial psoriatic arthritis 63
New approaches in tumor necrosis factor antagonism for the treatment of psoriatic arthritis: Certolizumab pegol 63
Recommendations for the use of biologics and other novel drugs in the treatment of psoriatic arthritis: 2017 update from the Italian Society of Rheumatology 63
Role of comorbidities in spondyloarthritis including psoriatic arthritis 63
Interplay between environmental factors, articular involvement, and HLA-B27 in patients with psoriatic arthritis 63
Identification of the clinical features distinguishing psoriatic arthritis and fibromyalgia 62
The radiological assessment of axial involvement in psoriatic arthritis: a validation study of the BASRI total and the modified SASSS scoring methods. 62
Totale 7.519
Categoria #
all - tutte 48.298
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.298


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019353 0 0 0 0 0 0 0 0 300 17 15 21
2019/20201.437 21 23 183 69 171 54 280 94 215 91 54 182
2020/20211.591 27 178 9 243 273 102 199 20 206 17 266 51
2021/2022968 51 252 16 31 55 28 29 106 141 154 43 62
2022/20235.018 535 121 102 392 245 377 21 221 2.665 149 84 106
2023/2024669 242 133 54 26 60 72 18 47 17 0 0 0
Totale 11.873